藤澤 康弘 , Taku Fujimura , Yota Sato , Kayo Tanita , Yumi Kambayashi , Atsushi Otsuka , Yasuhiro FUJISAWA , Koji Yoshino , Shigeto Matsushita , Takeru Funakoshi , Hiroo Hata , Yuki Yamamoto , Hiroshi Uchi , Yumi Nonomura , Ryota Tanaka , Megumi Aoki , Keisuke Imafuku , Hisako Okuhira , Naoko Wada , Hiroyuki Irie , Takanori Hidaka , Akira Hashimoto , Setsuya Aiba

Antibodies against programmed cell death protein 1, such as nivolumab and pembrolizumab, are widely used for treating various cancers, including advanced melanoma. Nivolumab significantly prolongs sur …

Frontiers in Oncology (8), 530, 2018-11

IR